Codiak Biosciences Inc. (CDAK) PT Lowered to $24 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CDAK Hot Sheet
Price: $0.06 --0%
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 8
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 8
Join SI Premium – FREE
Wedbush analyst David Nierengarten lowered the price target on Codiak Biosciences Inc. (NASDAQ: CDAK) to $24.00 (from $34.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- XPLR Infrastructure (XIFR) PT Lowered to $10 at Scotiabank
- JPMorgan Upgrades Koito Manufacturing Co Ltd. (7276:JP) (KOTMF) to Overweight
- Max Healthcare Institute Ltd (MAXHEALT:IN) PT Raised to INR935 at Kotak
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
